Tratamento da coccidioidomicose

Translated title of the contribution: The treatment of coccidioidomycosis

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for those with severe disease. Oral triazole antifungals have had a great impact on the management of coccidioidomycosis. Both fluconazole and itraconazole at 400 mg daily have been effective for various forms of coccidioidomycosis, including meningitis, although relapse after therapy is discontinued is a problem. Individuals with suppressed cellular immunity are at increased risk for symptomatic coccidioidomycosis and they include those with HIV infection, those on immunosuppressive medications, and those who have received a solid organ transplant. Pregnant women and African-American men have been identified as two other groups who are at an increased risk for symptomatic and severe infection.

Translated title of the contributionThe treatment of coccidioidomycosis
Original languageUndefined/Unknown
Pages (from-to)51-56
Number of pages6
JournalRevista do Instituto de Medicina Tropical de Sao Paulo
Volume57
DOIs
StatePublished - Sep 1 2015

Keywords

  • Antifungal therapy
  • Coccidioidomycosis
  • Fungi
  • Mycotic infections

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'The treatment of coccidioidomycosis'. Together they form a unique fingerprint.

  • Cite this